Palliating EGFR Inhibitor Rash in African American and Other Cancer Patients
缓解非裔美国人和其他癌症患者的 EGFR 抑制剂皮疹
基本信息
- 批准号:9274475
- 负责人:
- 金额:$ 38.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-04-01 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAdverse eventAfrican AmericanAndrogen AntagonistsAndrogen ReceptorAndrogensAntineoplastic AgentsBiopsyCancer PatientCetuximabClinical DataClinical TrialsColorectal CancerConsciousCutaneousDataDevelopmentDistressDouble-Blind MethodEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorExanthemaFaceFeasibility StudiesFriendsGenesGoalsHead and Neck CancerHormonesHospitalizationInterviewInvestigationKetoconazoleLeadLearningLifeLimb structureMalignant NeoplasmsMalignant neoplasm of lungMediatingMessenger RNAMethodologyMorbidity - disease rateNational Comprehensive Cancer NetworkPainPatientsPharmaceutical PreparationsPigmentsPruritusPublished CommentPublishingQualitative MethodsQualitative ResearchQuality of lifeRaceRandomizedReportingResearch PersonnelRiskSkinSocial isolationSymptomsTestingTimeUnited States Food and Drug AdministrationVisitandrogen sensitivecancer therapycohortdouble-blind placebo controlled trialemotional distressepidemiology studyethnic differenceexperiencehigh riskimprovedmalemelanocytemennovelnovel therapeuticsoverexpressionpalliatepalliativepatient orientedpsychologicpsychological distresspsychosocialracial diversityrandomized placebo controlled trialsocial
项目摘要
ABSTRACT
Epidermal growth factor receptor (EGFR) inhibitors comprise a commonly prescribed
class of drug that improves survival in patients with a variety of malignancies. Rash,
particularly on the face, is the most common adverse event and occurs in 50-90% of
patients, is severe in 10-20% of patients, lacks effective palliative options, and
sometimes requires stopping cancer therapy. We have published qualitative research
from patients who developed this rash and learned that it leads to cutaneous pain,
psychological distress, and social isolation. One patient stated, "My face looks so bad
that if I go see my friends, they say, 'What happened to you.' I am self-conscious about
that." Another commented, “I just told them they would be better off just calling me,
don't come visit.” Another described, "I can feel the itch and burn all over." Some
investigators have suggested that African American patients do not suffer these
symptoms. Here, we hypothesize that they do, that their pigmented skin might
camoflage the rash, but that this rash still causes them physical and psychological pain.
Building on our data (a 933-patient epidemiologic study that shows rash is worse in
men; pilot clinical trial data that show benefit with a topical anti-androgen; and an
androgen-dependent gene profile from skin biopsies from patients with EGFR inhibitor
rash) and on data from others (some melanocytes overexpress androgens and
androgen receptors), we hypothesize this rash is androgen-driven and that the topical
antiandrogen, ketoconazole, palliates it in all patients, including African American
cancer patients. In Aim #1, we will interview African American patients who have
developed this rash and will use novel qualitative methods to probe into their
hypothesized psychological and cutaneous distress. In Aim #2, we will conduct a
randomized, double-blinded, placebo-controlled trial with ketoconazole (a topical anti-
androgen) to determine whether this agent palliates rash within a racially diverse cohort
and to explore whether it does so by modulating androgen-dependent genes, as alluded
to above. The long-term goal of this line of investigation is to reduce suffering and
improve the quality of life of all patients -- including African American patients -- who
suffer from EGFR inhibitor-induced rash.
摘要
表皮生长因子受体(EGFR)抑制剂包括常用的处方药
一类可提高多种恶性肿瘤患者存活率的药物。皮疹,
尤其是在面部,是最常见的不良事件,发生在50%-90%的
10%-20%的患者病情严重,缺乏有效的姑息治疗选择,以及
有时需要停止癌症治疗。我们已经发表了定性研究
从出现这种皮疹的患者那里得知它会导致皮肤疼痛,
心理困扰和社会孤立。一位病人说:“我的脸看起来很糟糕。
如果我去看我的朋友,他们会说,‘你怎么了?’我对此感到难为情
另一位网友评论说,我只是告诉他们,给我打电话会更好,
别来探望我。“另一位网友描述说,“我能感觉到全身发痒和灼热。”一些人
调查人员表示,非裔美国人患者不会遭受这些痛苦。
症状。在这里,我们假设他们有,他们有色素的皮肤可能
伪装皮疹,但这种皮疹仍然会给他们带来身体和心理上的痛苦。
基于我们的数据(一项933名患者的流行病学研究表明,皮疹在
男性;显示局部抗雄激素有效的试点临床试验数据;以及
EGFR抑制剂患者皮肤活检中雄激素依赖性基因图谱的研究
皮疹)和来自其他细胞的数据(一些黑素细胞过度表达雄激素和
雄激素受体),我们假设皮疹是由雄激素驱动的,局部用药
抗雄激素酮康唑在所有患者中都能缓解,包括非裔美国人。
癌症患者。在目标1中,我们将采访那些患有
开发了这种皮疹,并将使用新的定性方法来探讨他们的
假想的心理和皮肤痛苦。在目标2中,我们将进行
含酮康唑的随机、双盲、安慰剂对照试验(一种外用抗癌药物
雄激素),以确定该药物是否缓解了种族差异队列中的皮疹
并探索它是否通过调节雄激素依赖基因来实现这一点,正如所暗示的那样
敬更高的。这项调查的长期目标是减少痛苦和
改善包括非洲裔美国人在内的所有患者的生活质量
患有EGFR抑制剂引起的皮疹。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Aminah Jatoi其他文献
Aminah Jatoi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Aminah Jatoi', 18)}}的其他基金
Older Sexual and Gender Minority Patients with Serious Illness: Program-Building to Identify and Address Needs
患有严重疾病的老年性和性别少数患者:建立项目以确定和满足需求
- 批准号:
10684915 - 财政年份:2022
- 资助金额:
$ 38.53万 - 项目类别:
Older Sexual and Gender Minority Patients with Serious Illness: Program-Building to Identify and Address Needs
患有严重疾病的老年性和性别少数患者:建立项目以确定和满足需求
- 批准号:
10523705 - 财政年份:2022
- 资助金额:
$ 38.53万 - 项目类别:
Palliating EGFR Inhibitor Rash in African American and Other Cancer Patients
缓解非裔美国人和其他癌症患者的 EGFR 抑制剂皮疹
- 批准号:
10599238 - 财政年份:2017
- 资助金额:
$ 38.53万 - 项目类别:
Palliating EGFR Inhibitor Rash in African American and Other Cancer Patients
缓解非裔美国人和其他癌症患者的 EGFR 抑制剂皮疹
- 批准号:
9934138 - 财政年份:2017
- 资助金额:
$ 38.53万 - 项目类别:
Palliating EGFR Inhibitor Rash in African American and Other Cancer Patients
缓解非裔美国人和其他癌症患者的 EGFR 抑制剂皮疹
- 批准号:
10381450 - 财政年份:2017
- 资助金额:
$ 38.53万 - 项目类别:
Mentoring and Research in Cancer Palliative Care
癌症姑息治疗的指导和研究
- 批准号:
8312330 - 财政年份:2008
- 资助金额:
$ 38.53万 - 项目类别:
Rash from EGFR Inhibitors: Characterization & Palliation of a Symptom Cluster
EGFR 抑制剂引起的皮疹:特征
- 批准号:
7503895 - 财政年份:2008
- 资助金额:
$ 38.53万 - 项目类别:
Rash from EGFR Inhibitors: Characterization & Palliation of a Symptom Cluster
EGFR 抑制剂引起的皮疹:特征
- 批准号:
7666950 - 财政年份:2008
- 资助金额:
$ 38.53万 - 项目类别:
Mentoring and Research in Cancer Palliative Care
癌症姑息治疗的指导和研究
- 批准号:
8126204 - 财政年份:2008
- 资助金额:
$ 38.53万 - 项目类别:
Mentoring and Research in Cancer Palliative Care
癌症姑息治疗的指导和研究
- 批准号:
7525230 - 财政年份:2008
- 资助金额:
$ 38.53万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 38.53万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 38.53万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 38.53万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 38.53万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 38.53万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 38.53万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 38.53万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 38.53万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 38.53万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 38.53万 - 项目类别: